Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer is a research paper published in Journal for ImmunoTherapy of Cancer (2022). On theSindex it has a DataRank of 0.655. It has been cited 78 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.655
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →H2020 ONCOBIOME
Grant: N°825410
Germano-French ANR Ileobiome
Grant: 19-CE15-0029-01
NIH
Grant: NCI P01 CA250927
AMMICa
Grant: US23/CNRS UMS3655
LabEx Immuno-Oncology
Grant: ANR-18-IDEX-0001
RHU Torino Lumière
Grant: ANR-16-RHUS-0008
French Government’s Investissement d’Avenir
Grant: ANR-10-LABX-69-01
NCI NIH HHS
Grant: R01 CA219154
Institut National du Cancer
Grant: unidentified
unidentified
European Commission
Grant: 825410
Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response.
FWCI
5.35
Citation Percentile
1.0%
Influential Citations
4
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 4 of Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer
Additional file 4 of Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer
Additional file 1 of Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer
Additional file 1 of Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer
Additional file 3 of Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer
Additional file 2 of Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer
Additional file 2 of Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer
Additional file 3 of Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer